OnCo
Cancers & treatments·Regimen libraryFirst line

Venetoclax + azacitidine

Checked 2026-09-09

Newly diagnosed AML unfit for intensive chemotherapy

One cycle

every 28 days
1781415212228Azacitidine: 75 mg/m², SubcutaneousAzacitidineVenetoclax: 100 mg day 1, 200 mg day 2, then 400 mg daily (cycle 1 ramp-up); often days 1-21 from cycle 2, OralVenetoclax
28-day cycle, until progressionSubcutaneousOral Daily oral course

Components

DrugDoseRouteDays
Azacitidine
Small-molecule hypomethylating agent (cytotoxic)
75 mg/m²SCD1-7
Venetoclax
Small-molecule BCL-2 inhibitor
100 mg day 1, 200 mg day 2, then 400 mg daily (cycle 1 ramp-up); often days 1-21 from cycle 2OralD1-28
Cycles
until progression
28-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine

Notes

  • Azole antifungals: reduce venetoclax to 100 mg (posaconazole) or 200 mg (voriconazole).
  • Marrow at day 21-28 of cycle 1; delay the next cycle if hypoplastic and in remission.

Used in

Acute myeloid leukaemiaMyelodysplastic syndromes / neoplasms (MDS)
Trials
VIALE-A
Products
AzacitidineVenetoclax

Source

VIALE-A, NEJM 2020

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

7+3 (cytarabine + anthracycline) ± midostaurin
Fit adults with newly diagnosed AML; midostaurin for FLT3-mutated disease (quizartinib for FLT3-ITD)
every 28 days × 1-2
ATRA + arsenic trioxide
Low or intermediate-risk acute promyelocytic leukaemia (WBC 10 × 10⁹/L or less)
every 28 days
All regimensATRA + arsenic trioxide →